PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions

Surg Pathol Clin. 2021 Jun;14(2):165-175. doi: 10.1016/j.path.2021.01.001. Epub 2021 Apr 28.

Abstract

PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited. Detection of PRAME protein expression by immunohistochemistry in a cohort of 400 melanocytic tumors showed diffuse nuclear immunoreactivity for PRAME in most metastatic and primary melanomas. In contrast, most nevi were negative for PRAME or showed nondiffuse immunoreactivity. The difference in the extent of immunoreactivity for PRAME in unambiguous melanocytic tumors prompted the study of PRAME as an ancillary tool for evaluating melanocytic lesions in more challenging scenarios.

Keywords: Immunohistochemistry; Melanoma; Nevus; PReferentially expressed Antigen in MElanoma.

Publication types

  • Review

MeSH terms

  • Antigens, Neoplasm
  • Humans
  • Immunohistochemistry
  • Melanoma* / diagnosis
  • Skin Neoplasms* / diagnosis

Substances

  • Antigens, Neoplasm
  • PRAME protein, human